ResMed is gearing up to release its first branded portable oxygen concentrator (POC), Mobi, which will be available to HME providers later this quarter.
Mobi will be designed to balance of oxygen delivery, weight and battery life to ensure patients with chronic obstructive pulmonary disease (COPD) and other respiratory conditions can enjoy a better quality of life while continuing to get oxygen therapy, according to a statement from ResMed. To achieve that, the device will build on the company’s work in portable sleep solutions, according to ResMed CEO Mick Farrell.
“We have focused decades of patient-centered ResMed technology and design innovation into this POC,” he said. “We’ve achieved great mobility, comfort and therapy quality in sleep apnea treatment with AirMini, the world’s smallest PAP device.”
The ResMed statement also highlighted the key role mobility plays in COPD treatment. Increased ambulation and regular physical activity is shown to reduce hospitalization and death for those patients, according to a 2006 study published in Thorax.
“Our patients demand a device that enables them to get out of their house and travel to visit friends and family. Mobi gives the gift of freedom to millions,” Farrell added.
In addition to launching Mobi in the U.S. market, ResMed reported it is pursuing clearance to sell in other countries in 2018, as well.